Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering.
An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening.
Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.
There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.
Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress.
There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2015. The largest expansion is expected between the years 2020 and 2025.
Profiles of 251 companies, out of over 500 involved in this area, are included in the last chapter along with their 180 collaborations. The report is supplemented with 45 Tables, 30 figures and 820 references to the literature.
Key Topics Covered:
Part I: Applications & Markets
Executive Summary
1. Introduction
2. Nanotechnologies
3. Nanotechnologies for Basic Research Relevant to Medicine
4. Nanomolecular Diagnostics
5. Nanopharmaceuticals
6. Role of Nanotechnology in Biological Therapies
7. Nanodevices & Techniques for Clinical Applications
8. Nanooncology
9. Nanoneurology
10. Nanocardiology
11. Nanopulmonology
12. Nanoorthopedics
13. Nanoophthalmology
14. Nanomicrobiology
15. Miscellaneous Healthcare Applications of Nanobiotechnology
16. Nanobiotechnology and Personalized Medicine
17. Nanotoxicology
18. Ethical and Regulatory Aspects of Nanomedicine
19. Research and Future of Nanomedicine
20. Nanobiotechnology Markets
21. References
Part II: Companies
22. Nanobiotech Companies
For more information about this report visit http://www.researchandmarkets.com/research/54pk6n/nanobiotechnology
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Nanotechnology


Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
First Western Ship Transits Strait of Hormuz Since Iran War Began
Apple Turns 50: From Garage Startup to AI Crossroads
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



